SPOTLIGHT: FDA accepts BioDelivery drug app

The FDA has accepted BioDelivery Sciences International's new drug application for its nausea and vomiting treatment, Emezine. The FDA now has about nine months to decide whether to approve the product. If it receives the FDA's blessing, Emezine would be the BioDelivery's first drug to hit the market. The company licensed the drug from Reckitt Benckiser Healthcare. Report

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.